Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates
Analysts from Barclays, Raymond James, and Baird all downgraded their ratings for Arcturus on Tuesday. Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021, on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies. Barclays analyst Gena Wang wrote that the interim data of the vaccine candidate was "disappointing," per Seeking Alpha. Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with t...
Source: businessinsider.in